← Eichor
Study identifier: NCT05537610 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Extensions of Resurgence as Choice

Condition: Problem Behavior · Aggression · Self-Injury  ·  Sponsor: Rutgers, The State University of New Jersey

PhaseNA
Planned participants30
Who can joinAll sexes, 3 Years to 17 Years
Healthy volunteersYes

About this study

Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the child their way in the natural environment (e.g., caregiver is busy with an infant sibling). This form of treatment relapse is known as resurgence. The goal of the current study is to evaluate whether alternating sessions in which the child can have their way (i.e., "on" sessions) with sessions in which the child can not have their way (i.e., "off" sessions) helps to mitigate resurgence.

This description comes directly from the study's public registry record.

Talk to the study team

Brian Greer, PhD  ·  8488008505  ·  brian.greer@rutgers.edu

Serena Claiborne  ·  8488008504  ·  SClaiborne@childrens-specialized.org

Always discuss trial participation with your own doctor first.

Locations (1)

Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and ServicesSomerset, New Jersey, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05537610